0000950170-24-057092.txt : 20240509 0000950170-24-057092.hdr.sgml : 20240509 20240509163032 ACCESSION NUMBER: 0000950170-24-057092 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240507 FILED AS OF DATE: 20240509 DATE AS OF CHANGE: 20240509 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: PERRY GREGORY D CENTRAL INDEX KEY: 0001236371 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37773 FILM NUMBER: 24931219 MAIL ADDRESS: STREET 1: C/O IMMUNOGEN, INC. STREET 2: 830 WINTER ST. CITY: WALTHAM STATE: MA ZIP: 02451 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Merus N.V. CENTRAL INDEX KEY: 0001651311 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: P7 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: YALELAAN 62 CITY: 3584 CM UTRECHT STATE: P7 ZIP: 3584 CM BUSINESS PHONE: 31 030 253 8800 MAIL ADDRESS: STREET 1: YALELAAN 62 CITY: 3584 CM UTRECHT STATE: P7 ZIP: 3584 CM FORMER COMPANY: FORMER CONFORMED NAME: Merus B.V. DATE OF NAME CHANGE: 20150819 4 1 ownership.xml 4 X0508 4 2024-05-07 0001651311 Merus N.V. MRUS 0001236371 PERRY GREGORY D C/O MERUS N.V. UPPSALALAAN 17 UTRECHT P7 3584 CT NETHERLANDS false true false false Chief Financial Officer & PFO false Share Option (right to buy) 36.09 2024-05-07 4 A false 107300 0 A 2034-01-31 Common Shares 107300 107300 D On February 1, 2024, the Board of Directors approved the grant of options to purchase the common shares, at an exercise price of $36.09 per share, subject to the Company's general meeting resolving upon, and the Board having implemented through an amendment to the Company's articles of association, an increase in the authorized share capital sufficient to satisfy the award set forth (the "Shareholder Approval Condition"). On May 7, 2024, the shareholders approved the amendment to the Company's articles of association, including the increase in the authorized share capital satisfying the Shareholder Approval Condition. Options vest over a four-year period from January 1, 2024. 25% vest on January 1, 2025 and in 36 equal monthly installments thereafter. /s/ Peter Silverman as attorney-in-fact 2024-05-09